APP and Alzheimer disease: In vitro studies reveal the selectivity and potency of FAH65, and in vivo studies in AD model mice provide evidence that FAH65 decreases APP cleavage product sAPPβ in brain tissue and increases trophic, neurite-supporting cleavage product sAPPα, along with significant improvements in memory in the NOR/NLR testing paradigms after oral treatment at 30 mkd for 26 days.